Stock data
Lexicon Pharmaceuticals, Inc. (LXRX)
Lexicon Pharmaceuticals, Inc. (LXRX) reported revenue of US$49.80M and net income of -US$50.34M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$49.80M | — | -US$48.91M | -US$50.34M | — |
| 2024 | US$6.00M | — | -US$197.12M | -US$200.40M | — |
| 2023 | US$1.11M | — | -US$171.75M | -US$177.12M | — |
| 2022 | US$0.00M | — | -US$100.76M | -US$101.94M | — |
| 2021 | US$0.00M | — | -US$87.09M | -US$87.76M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.69M | -US$31.77M | — |
| 2026-03-31 | US$21.10M | -US$1.04M | — |
| 2025-12-31 | US$5.49M | -US$15.53M | — |
| 2025-09-30 | US$14.18M | -US$12.77M | — |
| 2025-06-30 | US$28.87M | US$3.25M | — |
| 2025-03-31 | US$1.26M | -US$25.30M | — |
| 2024-12-31 | US$1.55M | -US$33.77M | — |
| 2024-09-30 | US$1.74M | -US$64.81M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.